Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix

Objective This study elucidated the efficacy of Relugolix (REL) on the reduction of uterine volume and clinical symptoms for the treatment of adenomyosis.Methods We conducted a retrospective cohort study of patients who received REL (40 mg for about 20 weeks) and who underwent a hysterectomy for ade...

Cijeli opis

Bibliografski detalji
Glavni autori: Keitaro Yamanaka, Keiichi Washio, Akiko Uchida, Yuki Sasagawa, Masashi Nishimoto, Yui Yamasaki, Satoshi Nagamata, Yoshito Terai
Format: Članak
Jezik:English
Izdano: Taylor & Francis Group 2023-12-01
Serija:Gynecological Endocrinology
Teme:
Online pristup:https://www.tandfonline.com/doi/10.1080/09513590.2023.2237121